Description
Pramipexole is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by some users of SSRI antidepressant drugs. Pramipexole has shown robust effects on pilot studies in bipolar disorder. Pramipexole is classified as a non-ergoline dopamine agonist.
Top Gene Interactions
Related Pathways
General Information
- Metabolism: No metabolites have been identified in plasma or urine. Route of Elimination: Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine. Half Life: 8 hours
- Uses/Sources: For the treatment of signs and symptoms of idiopathic Parkinson's disease
- Treatment: There is no known antidote for overdosage of a dopamine agonist. If signs of central nervous system stimulation are present, a phenothiazine or other butyrophenone neuroleptic agent may be indicated; the efficacy of such drugs in reversing the effects of overdosage has not been assessed. Management of overdose may require general supportive measures along with gastric lavage, intravenous fluids, and electrocardiogram monitoring. (L1712)
- Route of Exposure: Oral, rapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.
Mechanism of Action
Target Name | Mechanism of Action | References |
---|---|---|
5-hydroxytryptamine receptor 2A 5-hydroxytryptamine receptor 2C 5-hydroxytryptamine receptor 1A 5-hydroxytryptamine receptor 2B Alpha-2A adrenergic receptor 5-hydroxytryptamine receptor 1B 5-hydroxytryptamine receptor 1D D(1A) dopamine receptor Alpha-2B adrenergic receptor D(1B) dopamine receptor Alpha-2C adrenergic receptor |
18691132 10641988 |
|
D(2) dopamine receptor D(3) dopamine receptor D(4) dopamine receptor |
The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. |
11752352 23237836 12161137 10728880 16134944 |
Pramipexole Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Basal Ganglia Diseases | 9.92 |
|
Trigeminal Neuralgia | 9.11 |
|
Pituitary Neoplasms | 8.87 |
|
Reperfusion Injury | 8.42 |
|
Disruptive, Impulse Control, and Conduct Disorders | 7.82 |
|
Hyperprolactinemia | 7.57 |
|
Cocaine dependence | 6.82 |
|
Amphetamine-Related Disorders | 6.62 | |
Tremor hereditary essential, 1 | 6.46 |
|
Hyperalgesia | 6.32 |
|
Parkinsonian Disorders | 6.05 |
|
Myocardial Reperfusion Injury | 5.84 |
|
Disease Models, Animal | 5.65 |
|
Movement disorder | 5.59 |
|
Schizophrenia | 5.48 |
|
Precancerous Conditions | 5.46 |
|
Dyskinesia, Drug-Induced | 5.45 |
|
Cognitive impairment | 5.36 |
|
Gambling | 5.31 |
|
Myoclonic dystonia | 5.27 |
|